Orphazyme initiates rolling submission of New Drug Application for arimoclomol with US FDA in Niemann-Pick disease Type C

by | May 29, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces it has initiated the submission of its New Drug Application (NDA) for a rolling review by the US Food and Drug Administration (FDA) for arimoclomol, an investigational Heat-Shock Protein amplifier, for the treatment of Niemann-Pick disease Type C (NPC).


Press inquiries should be adressed to:

Sten Verland, PhD MSc

General Partner